Busch et al. investigated whether the immunomodulatory drug lenalidomide improved the anti-MM activity of myeloma-associated macrophages (MAMs) elicited by MOR202 (monoclonal antibody anti-CD38) and whether the VD pathway was a part of its modulating effect. The gene discussed is CD38; the disease is plasma cell myeloma.